PepEvolutionTirzepatide Dosage: What the Clinical Label and Trials Show
Tirzepatide · Mounjaro / Zepbound
Status & framing. Tirzepatide IS an FDA-approved drug (Mounjaro for type 2 diabetes; Zepbound for weight management), prescribed and dosed by a licensed clinician. The doses below are taken from the FDA label and pivotal trials for education. Compounded/gray-market vials carry counterfeit and dosing risk, this is not a recommendation to self-dose.
What the research shows
Unlike research-only peptides, tirzepatide has FDA-approved dosing. The label uses a stepwise titration that starts low to limit gastrointestinal side effects and increases every four weeks as tolerated. The SURMOUNT-1 obesity trial studied maintenance doses of 5, 10, and 15 mg once weekly.
Doses used in studies
Each row is a dose as reported in the cited source, not a recommendation. Superscripts link to sources below.
| Context | Dose studied | Route / frequency |
|---|---|---|
| FDA label, starting dose | 2.5 mg once weekly for 4 weeks[2]⚠ The 2.5 mg starting dose is a titration step, not a maintenance/therapeutic dose. | Subcutaneous, once weekly |
| FDA label, titration | Increase by 2.5 mg every ≥4 weeks as tolerated[2] | Subcutaneous, once weekly |
| SURMOUNT-1 (obesity), maintenance doses studied | 5 mg, 10 mg, or 15 mg once weekly[1] | Subcutaneous, once weekly |
| FDA label, maximum dose | 15 mg once weekly[2] | Subcutaneous, once weekly |
Reconstitution & example math
Branded tirzepatide (Mounjaro/Zepbound) ships as a prefilled pen, no reconstitution. For a compounded lyophilized 10 mg vial reconstituted with 1 mL of bacteriostatic water, concentration is 10 mg/mL. A 5 mg dose is then 0.5 mL, 50 units on a U-100 insulin syringe.
This math applies only to compounded lyophilized vials. Branded pens are pre-dosed and must not be redrawn. Compounded product carries counterfeit and mislabeling risk, verify a COA and use a licensed source.
Route, half-life & timing
Safety & side-effect notes from the literature
- Carries a boxed warning for thyroid C-cell tumors (seen in rodents); contraindicated with personal/family history of medullary thyroid carcinoma or MEN 2.[2]
- Most common adverse events are gastrointestinal, nausea, diarrhea, vomiting, constipation, which the stepwise titration is designed to reduce.[1][2]
- The FDA has warned about counterfeit and compounded semaglutide/tirzepatide products; gray-market vials are a documented dosing and purity risk.[3]
Frequently asked
What is the starting dose of tirzepatide?+
The FDA label starts at 2.5 mg subcutaneously once weekly for four weeks. This is a titration step to limit gastrointestinal side effects, not a maintenance dose.
What is the maximum tirzepatide dose?+
The FDA label maximum is 15 mg once weekly, reached by increasing 2.5 mg every four weeks or longer as tolerated. SURMOUNT-1 studied 5, 10, and 15 mg maintenance doses.
How do you reconstitute compounded tirzepatide?+
Branded pens need no reconstitution. For a compounded 10 mg lyophilized vial, adding 1 mL of bacteriostatic water gives 10 mg/mL; a 5 mg dose is 0.5 mL (50 units on a U-100 syringe). Verify a COA, compounded product carries counterfeit risk.
Get the full Tirzepatide protocol
PepEvolution Pro turns these research ranges into a personalized schedule, a full Tirzepatide protocol with a week-by-week plan, sourcing shortlist, and COA-checked vendors. Educational, cited, and built on the same methodology.
See what's in Pro →Email me the Tirzepatide protocol
Get this Tirzepatide dosing summary plus related reconstitution and sourcing guides. Research/educational only.
Sources & Citations
Primary sources only. Doses are stated as reported, see methodology.
Related
Educational only, not medical advice. Doses on this page are figures used in published research or clinical labeling, presented for education. They are not a prescription or a recommendation to self-administer. Consult a licensed healthcare provider before using any compound.